>
产品中心 >
RNA_interference >
SBI/pLL-CMV-rFLuc-T2A-GFP-mPGK-Puro晶状体贴标机和贸易；慢载体质粒&；预包装病毒/>；2×10^6 IFUs/LL310VA-1->；2×10^6 IFU
Overview
Reliable cell labeling, delivered
SBI’s family of Lenti-Labeler™ constructs facilitate a wide range of studies—including cell tracking, high-throughput assays, and more—by enabling efficient and reliable labeling of your cells. The pLL-CMV-rFLuc-T2A-GFP-mPGK-Puro Lenti-Labeler construct co-expresses rFLuc and GFP from the CMV promoter, which delivers strong expression in most commonly-used cell lines (HeLa, HEK293, HT-1080, etc.), and co-expresses the puromycin resistance gene for selection in vitro prior to in vivo use. Available as either fully propagatable, sequence-verified plasmid DNA (Cat.# LL310PA-1) or ready-to-transduce pre-packaged lentivirus (Cat.# LL310VA-1), SBI’s pLL-CMV-rFLuc-T2A-GFP-mPGK-Puro Lenti-Labeler is designed for reliability, so you can get to valuable insights faster.
- Proven—leverages SBI’s third generation lentivector technology for optimal virus titers
- Validated—sequence-verified from LTR to LTR and expression-verified in HT-1080 cells
- Flexible—available in a range of fluorescent markers, selection markers, and promoters (Table 1)
While the pLL-CMV-rFLuc-T2A-GFP-mPGK-Puro Lenti-Labeler construct is compatible with most second and third generation packaging plasmid mixes, SBI recommends the use of pPACKH1 (Cat #LV500A-1) and TransDux MAX Transduction Reagent (Cat #LV860A-1) to achieve optimal virus titers and infection of target cells.
Find the right Lenti-Labeler construct for your studies
SBI offers a Lenti-Labeler constructs with a range of selection markers, reporter genes, and two different promoters.
Table 1. Available Lenti-Labeler Constructs
| Cat. # | Construct | Promoter | Reporter | Selection |
|---|---|---|---|---|
| LL100PA-1/LL100VA-1 | pLL-CMV-GFP-T2A-Puro | CMV | GFP | Puromycin |
| LL105PA-1/LL105VA-1 | pLL-CMV-GFP-T2A-Blast | CMV | GFP | Blasticidin |
| LL110PA-1/LL110VA-1 | pLL-CMV-RFP-T2A-Puro | CMV | RFP | Puromycin |
| LL115PA-1/LL115VA-1 | pLL-CMV-RFP-T2A-Blast | CMV | RFP | Blasticidin |
| LL120PA-1/LL120VA-1 | pLL-CMV-BFP-T2A-Puro | CMV | BFP | Puromycin |
| LL125PA-1/LL125VA-1 | pLL-CMV-BFP-T2A-Blast | CMV | BFP | Blasticidin |
| LL150PA-1/LL150VA-1 | pLL-CMV-Luciferase-T2A-Puro | CMV | Luciferase | Puromycin |
| LL200PA-1/LL200VA-1 | pLL-EF1α-GFP-T2A-Puro | EF1α | GFP | Puromycin |
| LL205PA-1/LL205VA-1 | pLL-EF1α-GFP-T2A-Blast | EF1α | GFP | Blasticidin |
| LL210PA-1/LL210VA-1 | pLL-EF1α-RFP-T2A-Puro | EF1α | RFP | Puromycin |
| LL215PA-1/LL215VA-1 | pLL-EF1α-RFP-T2A-Blast | EF1α | RFP | Blasticidin |
| LL220PA-1/LL220VA-1 | pLL-EF1α-BFP-T2A-Puro | EF1α | BFP | Puromycin |
| LL225PA-1/LL225VA-1 | pLL-EF1α-BFP-T2A-Blast | EF1α | BFP | Blasticidin |
| LL250PA-1/LL250VA-1 | pLL-EF1α-Luciferase-T2A-Puro | EF1α | Luciferase | Puromycin |
| LL300PA-1/LL300VA-1 | pLL-CMV-rFLuc-T2A-GFP | CMV | Luciferase & GFP | N/A |
| LL310PA-1/LL310VA-1 | pLL-CMV-rFLuc-T2A-GFP-mPGK-Puro | CMV | Luciferase & GFP | Puromycin |
| LL320PA-1/LL320VA-1 | pLL-CMV-rFLuc-T2A-mRFP-mPGK-Puro | CMV | Luciferase & RFP | Puromycin |
| LL410PA-1/LL410VA-1 | pLL-EF1a-rFLuc-T2A-GFP-mPGK-Puro | EF1α | Luciferase & GFP | Puromycin |
| LL420PA-1/LL420VA-1 | pLL-EF1a-rFLuc-T2A-mRFP-mPGK-Puro | EF1α | Luciferase & RFP | Puromycin |
Supporting Data
SBI’s Lenti-Labelers get your cells labeled efficiently, reliably
Figure 1. SBI Lenti-Labeler constructs reliably and efficiently label cells. Comparison of the number of fluorescently-labeled cells to the total number of cells seen in the corresponding phase contrast images reveals the high labeling efficiency of SBI’s Lenti-Labeler constructs.
Figure 2. Dual reporter Lenti-Labeler vectors deliver robust fluorescence (A) and luminescence (B) signals. Data was obtained three days after infection of MDA-MB-231 cells with the dual reporter Lenti-Labeler Lentivirus CMV-rFLuc-T2A-GFP-mPGK-Puro (Cat #LL310VA-1). Infection efficiency was maximized by using SBI’s PEG-it Reagent (Cat.# LV810A-1) to concentrate the Lenti-Labeler Lentivirus prior to infection.
